Filing Details

Accession Number:
0001683168-16-000089
Form Type:
13D Filing
Publication Date:
2016-09-13 16:28:27
Filed By:
Roca Francisco Iii
Company:
Rennova Health Inc. (NASDAQ:RNVA)
Filing Date:
2016-09-13
SEC Url:
13D Filing
Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Francisco Roca, III 5,330,457 0 5,330,457 0 5,330,457 11.7%
Filing

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 2 )*

 

Rennova Health, Inc.


(Name of Issuer)

 

Common Stock, $.01 par value


(Title of Class of Securities)

 

759757 10 7


(CUSIP Number)

 

Francisco Roca, III

400 South Australian Avenue, 8th Floor

West Palm Beach, FL 33401

(561) 855-1626


(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

 

August 5, 2016


(Date of Event which Requires Filing of This Statement)

 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box [_].

 

Note:Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

 

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosure provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

   

 

CUSIP No. 759757 10 7   13D   Page 2 of 4 Pages
     
1.  

Names of Reporting Persons

 

Francisco Roca, III

   
2.  

Check the Appropriate Box if a Member of a Group

(see instructions)

(a)    ☐

(b)    ☐

   
3.  

SEC Use Only

 

   
4.  

Source of Funds (see instructions)

 

OO

   
5.   Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e)     ☐    
6.  

Citizenship or Place of Organization

 

United States

   
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH   7.  

Sole Voting Power

 

5,330,457

  8.  

Shared Voting Power

 

-0-

  9.  

Sole Dispositive Power

 

5,330,457

  10.  

Shared Dispositive Power

 

-0-

11.  

Aggregate Amount Beneficially Owned by Each Reporting Person

 

5,330,457

   
12.  

Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)   ☒

 

   
13.  

Percent of Class Represented by Amount in Row (11)

 

11.7%

   
14.  

Type of Reporting Person

 

IN

   

 

 

 

 2 

 

CUSIP No. 759757 10 7   13D   Page 3 of 4 Pages
     

 

 

 

Item 1. Security and Issuer

 

This Amendment No. 2 to Schedule 13D amends the Statement on Schedule 13D, dated November 2, 2015, as previously amended by Amendment No. 1 to Schedule 13D, with respect to the Common Stock, $0.01 par value per share (the "Shares"), of Rennova Health, Inc., a Delaware corporation (the "Issuer"), filed by Francisco Roca, III. Except as expressly amended below, the Schedule 13D, dated November 2, 2015, as previously amended, remains in effect.

.

Item 3. Source and Amount of Funds or Other Consideration

 

Item 3 is hereby amended to include the following:

 

This Amendment No. 2 to Schedule 13D is being filed to report the issuance to Mr. Roca on August 5, 2016 of 737,399 Shares (at $0.45 per Share), and 737,399 warrants to purchase a like number of Shares at an exercise price of $0.45 per Share. The warrants are currently exercisable and expire on August 5, 2026. The Shares and the warrants were issued to Mr. Roca by the Issuer in exchange for the cancellation of certain outstanding indebtedness owed by the Issuer to Mr. Roca.

 

Item 5. Interest in Securities of the Issuer

 

Item 5 is hereby amended to include the following:

 

As of August 5, 2016, Mr. Roca may be deemed to beneficially own 5,330,457 Shares (or approximately 11.7% of the total number of Shares deemed outstanding), which consists of (i) 2,593,058 Shares, (ii) 2,000,000 stock options owned of record by Mr. Roca to purchase a like number of Shares, and (iii) 737,399 warrants owned of record by Mr. Roca, as described in Item 3. above, to purchase a like number of Shares; all as to which Mr. Roca has sole dispositive and voting power. Such Shares do not include 1,000 shares of the Issuer's Series B Convertible Preferred Stock, owned of record by Mr. Roca.

 

 

 3 

 

 

 

SIGNATURES

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

 

  September 13, 2016   /s/ Francisco Roca, III                         
      Francisco Roca, III
       
       
       

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 4